⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25908908 | 0.76 | — | — | |
| SCHEMBL12348439 | 0.74 | — | — | |
| SCHEMBL12348438 | 0.72 | — | — | |
| SCHEMBL19002512 | 0.66 | — | — | |
| SCHEMBL12604026 | 0.59 | — | — | |
| SCHEMBL17904739 | 0.57 | — | — | |
| SCHEMBL15982096 | 0.56 | — | — | |
| SCHEMBL10692602 | 0.56 | — | — | |
| SCHEMBL10141701 | 0.55 | — | — | |
| SCHEMBL9616051 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040131-A1 | PYRIDOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| WO-2023283263-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-03-19 | — | — | US | disclosed |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2017-01-26 | — | — | US | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8623869-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |